- Joined
- Jul 9, 2013
- Messages
- 5
- Reaction score
- 0
Yau T, Tang VYF, Yao TJ, et al. Development of Hong Kong cancer staging system with treatment statification for patients with hepatocellular carcinoma. Gastroenterology 2014 (available online).
Brief Summary: Authors looked at 3856 patients with HCC (mostly 2/2 to Hep B) treated from 1/955 to 12/2008. Included performance status, Child-Pugh grade, tumor status and presence of extrahepatic vascular invasion or mets. Authors found HKLC had a better ability than BCLC to determine specific overall survival times and allowed for subsets of what would constitute BCLC intermediate- and advanced-stage patients to get more aggressive treatments and improved survival outcomes (e.g., HKLC-II v BCLC-B/C).
Several medical centers are discussing replacing BCLC with HKLC. Any thoughts about advantages/disadvantages? What does your hospital typically use now?
Brief Summary: Authors looked at 3856 patients with HCC (mostly 2/2 to Hep B) treated from 1/955 to 12/2008. Included performance status, Child-Pugh grade, tumor status and presence of extrahepatic vascular invasion or mets. Authors found HKLC had a better ability than BCLC to determine specific overall survival times and allowed for subsets of what would constitute BCLC intermediate- and advanced-stage patients to get more aggressive treatments and improved survival outcomes (e.g., HKLC-II v BCLC-B/C).
Several medical centers are discussing replacing BCLC with HKLC. Any thoughts about advantages/disadvantages? What does your hospital typically use now?